Tirzepatide for MASH Liver Disease: FDA Approves First Drug for Metabolic Liver Condition
Quick Facts
What Is Tirzepatide and How Does It Treat MASH?
Tirzepatide works by simultaneously activating glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, improving insulin sensitivity, reducing hepatic fat accumulation, and lowering systemic inflammation. In the phase 2 SYNERGY-NASH trial published in the New England Journal of Medicine in 2024, patients receiving 15 mg weekly demonstrated substantial reductions in liver fat content measured by MRI-PDFF compared to placebo.
The drug's mechanism addresses the metabolic root causes of MASH rather than merely managing symptoms. By improving adipose tissue function and reducing lipotoxicity, tirzepatide targets the cycle of hepatocyte injury, inflammation, and progressive fibrosis that characterizes the disease. Tirzepatide joins resmetirom (Rezdiffra), which was approved in March 2024 as the first-ever MASH pharmacotherapy, giving clinicians a second treatment option with a distinct mechanism of action. The FDA granted breakthrough therapy designation to tirzepatide for MASH, reflecting the significant unmet medical need for millions of Americans with the condition, many of whom face limited treatment options as the disease progresses.
What Did Clinical Trials for Tirzepatide in MASH Show?
The phase 2 SYNERGY-NASH trial enrolled approximately 190 adults with biopsy-confirmed MASH and fibrosis stages F2–F3. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo. The primary endpoint—MASH resolution without worsening fibrosis—was achieved by approximately 44%, 56%, and 62% of patients in the respective dose groups versus 10% with placebo. Fibrosis improvement by at least one stage was also significantly higher in the tirzepatide groups compared to placebo. Subsequent larger-scale phase 3 trials have further evaluated tirzepatide's efficacy in a broader patient population.
Adverse events were consistent with the known GLP-1 receptor agonist class profile: nausea, diarrhea, and decreased appetite, most of which were mild-to-moderate and transient. Patients also experienced clinically meaningful weight reduction, providing additional cardiovascular and metabolic benefits. Hepatologists have described the results as highly promising, and the American Association for the Study of Liver Diseases (AASLD) is expected to incorporate tirzepatide into updated treatment guidance for eligible MASH patients.
Who Is Eligible for Tirzepatide MASH Treatment?
The approved indication covers adults aged 18 and older with non-cirrhotic MASH and liver fibrosis stages F2 or F3, confirmed by liver biopsy or validated non-invasive testing combined with clinical assessment. The drug is contraindicated in patients with decompensated cirrhosis, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 — consistent with the established safety profile of GLP-1-based therapies.
Gastroenterologists and hepatologists note that a practical challenge will be identifying eligible patients, as MASH is frequently underdiagnosed. Many patients are unaware they have the condition until it has progressed significantly. The FDA label encourages the use of non-invasive fibrosis screening tools such as FIB-4 and enhanced liver fibrosis (ELF) tests for initial assessment, followed by confirmatory imaging or biopsy. As with other GLP-1 receptor agonist therapies, cost and insurance coverage will be important factors in patient access. Eli Lilly has indicated that patient support programs will be available for eligible individuals.
Frequently Asked Questions
Yes, tirzepatide is the same molecule marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The MASH indication uses the same weekly subcutaneous injection at doses of 5–15 mg. Whether the MASH indication will be marketed under the existing brand names or a separate brand name may vary by region.
The phase 2 clinical trial demonstrated benefits at 52 weeks, and longer-term studies are evaluating extended use. Current guidance suggests continued therapy as long as clinical benefit is maintained, as MASH may recur upon discontinuation in some patients.
In the phase 2 SYNERGY-NASH trial, a significant proportion of patients on the highest dose achieved at least one stage of fibrosis improvement. Results varied by baseline fibrosis severity, with earlier-stage fibrosis (F2) generally showing better responses than advanced fibrosis (F3). Complete reversal of fibrosis remains an area of ongoing research.
References
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299–310.
- U.S. Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA News Release, March 14, 2024.
- Rinella ME, Lazarus JV, Ratziu V, et al. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. Hepatology. 2023;78(6):1966–1986.